%0 Editorial
%T Minimally invasive pelvic exenteration for primary or recurrent locally advanced rectal cancer: A glimpse into the future.
%A Kehagias D
%A Lampropoulos C
%A Kehagias I
%J World J Gastrointest Surg
%V 16
%N 7
%D 2024 Jul 27
%M 39087129
暂无%R 10.4240/wjgs.v16.i7.1960
%X Surgeons have grappled with the treatment of recurrent and T4b locally advanced rectal cancer (LARC) for many years. Their main objectives are to increase the overall survival and quality of life of the patients and to mitigate postoperative complications. Currently, pelvic exenteration (PE) with or without neoadjuvant treatment is a curative treatment when negative resection margins are achieved. The traditional open approach has been favored by many surgeons. However, the technological advancements in minimally invasive surgery have radically changed the surgical options. Recent studies have demonstrated promising results in postoperative complications and oncological outcomes after robotic or laparoscopic PE. A recent retrospective study entitled "Feasibility and safety of minimally invasive multivisceral resection for T4b rectal cancer: A 9-year review" was published in the World Journal of Gastrointestinal Surgery. As we read this article with great interest, we decided to delve into the latest data regarding the benefits and risks of minimally invasive PE for LARC. Currently, the small number of suitable patients, limited surgeon experience, and steep learning curve are hindering the establishment of minimally invasive PE.